Tagged Articles

ankylosing spondylitis 2 articles

Labels on TNFa blockers get stronger warning

The black box warning for a class of immunosuppressant drugs known as Tumor Necrosis Factor-alpha (TNFa) blockers is being updated to include the risk of potentially deadly infections from two bacterial pathogens, Legionella and Listeria. TNFa blockers are biologic products that include Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab pegol), and Simponi (golmumab). TNFa blockers are drugs used to treat Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, and/or juvenile idiopathic arthritis. Since TNFs blockers are immunosuprresants, patients who take these drugs are at increased risk of serious, including fatal, infections. These infections can involve ... Read More

New arthritis drug linked to SJS, TEN

A newly approved drug for the treatment of arthritis in patients at risk of developing NSAID-associated gastric ulcers has been linked to a rare but serious hypersensitivity disorder known as Stevens Johnson Syndrome (SJS). VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets by AstraZeneca and POZEN, has been approved by the Food and Drug Administration (FDA) for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The medication is also designed to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated ulcers. The fixed dose of the pain-relieving non-steroidal anti-inflammatory (NSAID) drug ... Read More